Chronic graft-versus-host disease
Conditions
Interventions
Belumosudil mesylate tablets treatment:None
Sponsors
Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Children who have undergone allogeneic hematopoietic stem cell transplantation; 2. Children diagnosed as having active moderate to severe cGVHD according to the NIH consensus diagnostic and staging criteria, and who are scheduled to receive treatment with belumosudil mesylate tablets; 3. Under the age of 18, regardless of gender; 4. The subjects and their guardians are willing to follow the procedures and operations stipulated in the research protocol; 5. The subjects and their guardians are willing and able to provide written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. It is known that the subject is allergic to the research drug or its components; 2. The researcher believes that the child's current condition may interfere with participation in the study or present other unsuitable circumstances for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall response rate;Overall survival; | — |
Countries
China
Contacts
Public ContactWu Juan
Shanghai Children’s Medical Center,Shanghai Jiao Tong University School of Medicine
Outcome results
None listed